Tong Lin

Tong Lin has extensive work experience in the pharmaceutical industry. Currently, they are serving as the Executive Director and Head of Clinical Pharmacology at REVOLUTION Medicines since 2023. Prior to this, they worked at Jazz Pharmaceuticals from 2016 to 2023, where they held the role of Director of Clinical Pharmacology. During their time at Jazz Pharmaceuticals, they played a pivotal role in obtaining the US approval for Rylaze in ALL/LBL patients and was involved in the real-time oncology review program with the FDA. Before Jazz Pharmaceuticals, Tong Lin worked at Medivation as the Director of Clinical Pharmacology and DMPK from 2013 to 2016. Tong also served as the Associate Director and Head of Preclinical Development at Geron Corporation from 2007 to 2013. Tong Lin began their career as a Staff Scientist at Rigel in 1997 and has also held positions at Celera Genomics and ArQule.

Tong Lin attended Peking University, where they obtained a B.S. degree in Chemistry. Later, they pursued further education at the University of North Carolina at Chapel Hill, where they earned a Ph.D. in Analytical Chemistry. The provided information does not include the specific years of study or any additional education history beyond these degrees.